Abstract: The present invention relates to the use of a substrate for enhancing the chemiluminescence of one or more luminophores produced in a chemiluminescence reaction, wherein the substrate comprises a solid polymeric carrier with a plurality of depressions separated from one another and that the solid carrier is at least partially coated with a metal.

Abstract: The present invention relates to the use of a substrate for enhancing the fluorescence of a fluorescent molecule, wherein the substrate comprises a solid polymer carrier having a plurality of recesses separated from each other and wherein the solid carrier is coated at least in part by a metal.

Abstract: The present invention relates to a method for diagnosing a liver disease in a mammal comprising the step of determining the amount of a product encoded by the NOG gene in a biological fluid sample of said mammal and diagnosing a liver disease if the amount of the product encoded by the NOG gene in the sample of said mammal is different from the amount of the product encoded by the NOG gene determined in a sample of a healthy mammal.

Abstract: The present invention relates to the use of a substrate for enhancing the fluorescence of a fluorescent molecule, wherein the substrate comprises a solid polymer carrier having a plurality of recesses separated from each other and wherein the solid carrier is coated at least in part by a metal.

Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof for the diagnosis of heart disease, comprising the steps of providing a feline or canine sample, contacting the sample with at least one species-specific antibody for binding to at least one epitope of the respective species proBNP, determining the concentration of at least one fragment of proBNP, and diagnosing the animal with heart disease if the concentration is elevated compared to healthy subjects.

Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.

Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.

Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.

Abstract: The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels.

Abstract: The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels.

Abstract: The present invention is directed to methods for the detection and diagnosis of bone and/or cartilage disorders, wherein the level of expression of a polypeptide in a test sample is measured by contacting the test sample with an antibody that specifically binds to said polypeptide and measuring the binding of said antibody to said test sample.

Abstract: The invention relates to a method of determining equine NT-proBNP, or fragments thereof, comprising the steps of: providing an equine sample, contacting the sample with at least one antibody which specifically binds to equine NT-proBNP, and determining the presence and/or concentration of the equine NT-proBNP or fragments thereof existing in the sample.

Abstract: Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 32 to 48 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.

Abstract: Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.

Abstract: Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.

Abstract: The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of providing a feline or canine sample, contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.